Key result
Triple antithrombotic therapy remains the most common post-PCI regimen in AF, prescribed to ~63%.
Why the study?
In patients with AF undergoing PCI, selecting an antithrombotic regimen requires balancing risks of ischemic cardiac events, stroke, and bleeding, prompting evaluation of real-world initial antithrombotic therapy selection patterns.
Cross-Sectional (n=467)
Yes
In Canadian practice, triple antithrombotic therapy remains the most common initial strategy for AF patients undergoing PCI, though dual-pathway therapy is increasingly utilized, particularly in patients with less complex coronary disease.
Answers are grounded in this paper and cite their sources.
Triple antithrombotic therapy remains predominant in Canadian AF-PCI practice; leaves open optimal regimen selection as dual-pathway use rises in lower-risk patients.
BackgroundIn patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), selecting an antithrombotic regimen requires balancing risks of ischemic cardiac events, stroke, and bleeding.MethodsWe studied 467 patients with AF undergoing PCI in the time period from December 2015 to July 2018 identified via a chart audit by 47 Canadian cardiologists in the CONNECT AF+PCI (the Coordinated National Network to Engage Interventional Cardiologists in the Antithrombotic Treatment of Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) study, to determine patterns of initial antithrombotic therapy selection.ResultsThe median (25th, 75th percentile) CHADS2 score was 2 (1, 3), and PCI was performed in the setting of acute coronary syndrome in 62.1%. Triple antithrombotic therapy (TAT) was the initial treatment in 62.7%, dual-pathway therapy in 25.7%, and dual antiplatelet therapy in 11.6%, with a temporal increase in use of dual-pathway therapy during the course of the study; median intended TAT duration was 1 (1, 3) month. Compared with patients selected for TAT, patients selected for dual-pathway therapy were less likely to have prior myocardial infarction (35.8% vs 25.8%, P = 0.045) and prior PCI (33.8% vs 23.3%, P = 0.03), and they received shorter total length of stents (38 [23, 56] vs 30 [20, 46] mm, P = 0.03). Patients selected for dual-pathway therapy had a higher prevalence of prior stroke/transient ischemic attack (13.0% vs 23.3%, P = 0.01). There was no difference in prevalence of anemia (21.5% vs 25.8%, P = 0.30). Use of dual-pathway therapy was similar among patients with acute coronary syndrome and those with stable disease (24.1% vs 28.2%, P = 0.32).ConclusionsApproximately one-quarter of AF patients undergoing PCI are treated with dual-pathway therapy in Canadian practice, with its use increasing during the studied period. Patients selected for dual-pathway therapy have less-complex coronary disease history and intervention.
No takes yet. Share an insight, caveat, or question.
Valle et al. (2021) conducted a cross-sectional in Atrial fibrillation in patients undergoing percutaneous coronary intervention (n=467). Dual-pathway therapy vs. Triple antithrombotic therapy (TAT) or Dual antiplatelet therapy (DAPT) was evaluated on Proportion of patients treated initially with DAPT, dual-pathway therapy, or TAT. Among atrial fibrillation patients undergoing PCI in Canada, triple antithrombotic therapy was the most common initial regimen, followed by dual-pathway therapy and dual antiplatelet therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: